The model also suggested that an anti-inflammatory drug called celecoxib should bind with CDH11, a protein which plays an important role in the development of both rheumatoid arthritis and metastatic breast cancer.
Kadcyla, known as an "antibody-drug conjugate, " represents "a completely new way" to treat HER2 positive metastatic breast cancer, said Dr. Hal Barron, chief medical officer and head of global product development for Genentech.